AMPLY Discovery is a drug and nutraceutical discovery company based in Northern Ireland. A spin-out company from Queen's University Belfast, we use machine learning and AI to discover new therapeutic molecules for hard-to-treat diseases. This includes developing new drugs to replace conventional antibiotics and help tackle AMR. Our discovery platform is designed to mine vast biological datasets in silico and validate hundreds of hits in vitro. Life is increasingly digitised. From individual organisms (genomes) to entire environments (metagenomes). This digital biome contains a near infinite supply of novel molecules for human and animal bioclinical use.

AMPLY Discovery Ltd was founded in February 2021 as spin-out from Queen’s University of Belfast with the goal of using the AMPLY platform to develop new biological molecules for anti-infective health and nutrition applications in animal and human health. AMPLY has been part of the BioAccelerate Wales, Lean Launch Programme NI and ICURe pre-accelerators, and EIT Food Seedbed programme. We have now been awarded a significant grant from the Innovate UK to support further development. We are currently discussing our pipeline with prospective partners to deliver our discoveries to market across animal health problems with a focus on topical skin and tissue infection management.